Key result
CYP2C9 variants and corticosteroid use linked to faster target INR and lower warfarin requirements.
Why the study?
Warfarin dosing algorithms do not include genetic factors or drug interactions, complicating clinical management in children with cancer.
Observational (n=29)
Answers are grounded in this paper and cite their sources.
Should not yet change warfarin dosing in pediatric oncology; leaves open prospective validation of CYP2C9-guided therapy in children.
Clinical management of warfarin therapy is complex, and dosing algorithms do not include genetic factors or interactions with other drugs for warfarin dose determinations. We evaluated the interaction of warfarin and CYP2C9 polymorphisms and concomitant corticosteroids in 29 children with cancer. Children with heterozygous polymorphisms of CYP2C9 achieved target INR sooner and more frequently had INR above the target level, compared to children without mutations. Children on concomitant steroids had significantly lower warfarin requirements. Thus, awareness of CYP2C9 genotype and steroid-induced responsiveness to warfarin may be important when administrating oral anticoagulation in children.
No takes yet. Share an insight, caveat, or question.
Ruud et al. (2007) conducted an observational in Cancer (n=29). CYP2C9 heterozygous polymorphisms and concomitant corticosteroids vs. Children without CYP2C9 mutations or not taking concomitant steroids was evaluated on Time to target INR, frequency of INR above target, and warfarin dose requirements. Heterozygous CYP2C9 polymorphisms and concomitant corticosteroid use in 29 children with cancer were significantly associated with faster target INR achievement and lower warfarin requirements.
Synapse has enriched 10 related papers. Consider them for comparative context: